Camber Pharmaceuticals has one of the fastest-growing portfolios in the U.S. generic drug industry. We are committed to developing and delivering high-quality, affordable, life-saving medications throughout the United States. While new product launches are essential to supporting our customers and the patients they serve, it’s equally important for Camber to highlight key legacy products that continue to provide value.
Valganciclovir Tablets
In 2016, Camber introduced Valganciclovir Tablets (generic for Valcyte®) as part of our antiviral portfolio expansion. Valganciclovir is indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for the prevention of CMV disease in high-risk kidney, heart, and kidney-pancreas transplant recipients.
Oxcarbazepine Oral Suspension
Nearly 3 million Americans reported some seizure episode in 2024. To strengthen our Anticonvulsants product line, Camber introduced Oxcarbazepine Oral Suspension (generic for Trileptal®) in early 2024. Oxcarbazepine is indicated for the treatment of partial-onset seizures.
Venlafaxine ER Tablets
Approximately 30% of Americans experience challenges with depression or anxiety disorders at some point in life. Venlafaxine Extended-Release Tablets (generic for Effexor®) are indicated for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.
Efavirenz Tablets
Approximately 1.2 million Americans are living with HIV. While there is no cure, modern therapies help suppress the virus and improve long-term health outcomes. Camber expanded its antiretroviral portfolio in 2018 with Efavirenz Tablets (generic for Sustiva®). Efavirenz is indicated as part of combination antiretroviral therapy for the treatment of HIV-1 infection.
Contact your Camber representative to learn more about these products.
